ADCE-202 / Adcendo - LARVOL DELTA

Efficacy of novel urokinase plasminogen activator receptor-associated protein targeted antibody-drug conjugates in patient-derived xenografts of soft tissue sarcoma (AACR 2025) - "Mice were randomized for the following treatments: (1) vehicle control, (2) doxorubicin, (3) targeted antibody ("naked" antibody without payload), (4) ADC-isotype control (deruxtecan linked to a non-specific antibody), (5) uPARAP-targeted ADC. In general, the novel uPARAP-targeted ADCs ADCE-017 and ADCE-202 showed superior anti-tumor effect in all three soft tissue sarcoma models as compared to vehicle control without any treatment-related side effects. These results warrant further preclinical studies in other types of sarcoma and a clinical evaluation of the ADCs as a potential new treatment option for soft tissue sarcoma."

Clinical • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor